Temasek Holdings Private Ltd Takes Position in Pfizer Inc. $PFE

Key Points

• Temasek Holdings Private Ltd acquired 520,900 shares of Pfizer Inc., valued at approximately $13.2 million, marking a significant investment in the biopharmaceutical company.
• Pfizer's stock saw a 1.3% increase recently, with a current market capitalization of $141.31 billion and a PE ratio of 13.22.
• The company announced a quarterly dividend of $0.43 per share, reflecting an annual yield of 6.9%, with a payout ratio of 91.49%.

Temasek Holdings Private Ltd purchased a new stake in Pfizer Inc. (NYSE:PFE - Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 520,900 shares of the biopharmaceutical company's stock, valued at approximately $13,200,000.

Several other institutional investors have also recently bought and sold shares of the business. UniSuper Management Pty Ltd raised its stake in Pfizer by 3.6% during the first quarter. UniSuper Management Pty Ltd now owns 362,283 shares of the biopharmaceutical company's stock worth $9,180,000 after acquiring an additional 12,538 shares in the last quarter. Raab & Moskowitz Asset Management LLC raised its stake in Pfizer by 2.3% during the first quarter. Raab & Moskowitz Asset Management LLC now owns 292,057 shares of the biopharmaceutical company's stock worth $7,401,000 after acquiring an additional 6,490 shares in the last quarter. Plancorp LLC raised its stake in Pfizer by 7.5% during the first quarter. Plancorp LLC now owns 105,355 shares of the biopharmaceutical company's stock worth $2,670,000 after acquiring an additional 7,374 shares in the last quarter. New England Asset Management Inc. raised its stake in Pfizer by 0.7% during the first quarter. New England Asset Management Inc. now owns 155,448 shares of the biopharmaceutical company's stock worth $3,939,000 after acquiring an additional 1,025 shares in the last quarter. Finally, NFJ Investment Group LLC grew its stake in shares of Pfizer by 103.6% during the first quarter. NFJ Investment Group LLC now owns 1,605,974 shares of the biopharmaceutical company's stock worth $40,695,000 after buying an additional 817,137 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer Trading Down 1.3%

PFE traded down $0.33 during trading on Monday, reaching $24.55. 49,188,016 shares of the stock traded hands, compared to its average volume of 34,669,424. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The stock has a market capitalization of $139.56 billion, a PE ratio of 13.06, a P/E/G ratio of 0.88 and a beta of 0.55. The stock's 50-day moving average is $24.85 and its 200 day moving average is $24.32. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $30.43.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.58 by $0.20. The company had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company's quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter last year, the firm posted $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 2nd. Investors of record on Friday, July 25th were issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.0%. The ex-dividend date was Friday, July 25th. Pfizer's dividend payout ratio (DPR) is currently 91.49%.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the stock. HSBC decreased their target price on shares of Pfizer from $27.00 to $26.00 and set a "buy" rating on the stock in a research note on Monday, May 19th. Morgan Stanley boosted their target price on shares of Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a research note on Wednesday, August 6th. Berenberg Bank lowered their price objective on Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a research note on Thursday, May 29th. Bank of America upped their price objective on Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a research note on Wednesday, August 6th. Finally, Jefferies Financial Group upped their price objective on Pfizer from $32.00 to $33.00 and gave the company a "buy" rating in a research note on Wednesday, May 21st. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, Pfizer currently has a consensus rating of "Hold" and a consensus target price of $28.12.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.